Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02516670 · ClinicalTrials.gov registry record · Phase 2
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT02516670 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 50 participants.
The verdict
NCT02516670, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well docetaxel works when given with or without ascorbic acid in treating patients with prostate cancer that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ascorbic acid (vitamin C) is a water-soluble vitamin that may help inhibit the growth of cancer cells. It is not yet known whether docetaxel works better when given with or without ascorbic acid in treating prostate cancer.
Interventions
- DRUG Docetaxel
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DIETARY_SUPPLEMENT Ascorbic Acid
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-06-20 |
| Est. Completion | 2021-10-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02516670
The ClinicalTrials.gov registry entry for NCT02516670 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT02516670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02516670 about?
NCT02516670 is a clinical study titled "Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer". This randomized phase II trial studies how well docetaxel works when given with or without ascorbic acid in treating patients with prostate cancer that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, eit...
What is the current status of trial NCT02516670?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2016-06-20. Estimated completion is 2021-10-14.
What interventions are being tested in trial NCT02516670?
The interventions under investigation include: Docetaxel (DRUG), Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Ascorbic Acid (DIETARY_SUPPLEMENT), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02516670?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.